The phase 1 CTEP #10355 trial presented at AACR 2026 represents more than incremental dosing tweaks—it addresses a persistent structural problem in precision oncology: how to harness mechanistic synergy between PARP inhibitors and topoisomerase-1 payloads without triggering unacceptable myelosuppression. Principal investigator Dr. Elizabeth Lee and colleagues tested trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate delivering a potent TOP1 inhibitor, alongside olaparib in 28 patients with heavily pretreated HER2-expressing ovarian (n=16) and uterine (n=12) cancers. This was a classic dose-escalation design, not a randomized controlled trial, limiting causal inferences about efficacy.

Original coverage correctly notes that Module 2 (standard-dose T-DXd every three weeks plus intermittent olaparib days 8-14) proved most tolerable, slashing grade 3 neutropenia from 30% in Module 1 to 12% and grade 3 anemia from 70% to 25%. Yet it understates the study's small sample size, the absence of a control arm, and limited follow-up for known T-DXd risks such as interstitial lung disease, which has reached 15% incidence in larger monotherapy trials. No conflicts of interest were disclosed in the abstract, though both agents have substantial industry backing.

Preclinical foundations are robust: a 2019 Cancer Research paper (Liu et al., n= preclinical models) demonstrated that PARP trapping amplifies unrepaired DNA breaks from TOP1 inhibition, creating synthetic lethality. Earlier clinical attempts pairing olaparib with conventional irinotecan or topotecan failed precisely because of overlapping hematologic toxicity (see phase 1 data in JCO 2017, n=53, DLT rate >40%). By replacing free chemotherapy with an ADC that preferentially releases payload in tumor cells, investigators widened the therapeutic index—an approach consistent with the broader evolution seen in DESTINY-Breast04 (NEJM 2022; randomized phase 3, n=557), where T-DXd doubled progression-free survival versus chemotherapy in HER2-low breast cancer.

What existing coverage missed is the signal across HER2 expression levels. Responses occurred regardless of IHC score, echoing emerging data from DESTINY-PanTumor02 (J Clin Oncol 2024; phase 2, n=267, ORR 37% with T-DXd monotherapy in HER2+ non-breast tumors). The 46% confirmed objective response rate and 15.2-month median PFS observed here exceed monotherapy benchmarks, yet must be interpreted cautiously given the enriched population and lack of randomization. The intermittent schedule appears to allow DNA repair recovery in normal tissues while maintaining tumor sensitization—an intelligent scheduling insight that could inform dozens of future ADC–PARPi combinations beyond HER2.

This work fits a larger pattern: the oncology community is shifting from blunt combinations to pharmacologically rational, toxicity-optimized regimens. If dose-expansion cohorts confirm these findings, the regimen could expand the pool of patients who tolerate and benefit from dual DNA-damage targeting. However, only properly powered randomized trials can determine whether the observed activity represents true additive or synergistic benefit versus patient selection. For now, Module 2 dosing offers a credible path forward that prioritizes both efficacy and quality of life in a population with few tolerable options.